EUCTR2008-004522-16-SK进行中（未招募）1 期
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF) - ENGAGE AF TIMI-48
Daiichi Sankyo Pharma Development0 个研究点目标入组 20,500 人开始时间: 2009年2月5日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female subjects with age = 21 years;
- •2.Able to provide written informed consent;
- •3.History of AF documented by a 12-lead electrocardiographic reading and/or continuous electrocardiogram (ECG) (e.g., Holter monitoring) consistent with AF (notation of AF as the abnormal rhythm on the local ECG report with evidence of irregularly irregular rhythm and an absence of P-waves on the ECG for diagnosis of AF) within the prior 12 months and for which anticoagulation therapy is indicated and planned for the duration of the study, including subjects with paroxysmal, persistent, or permanent AF and subjects with or without previous VKA (including warfarin) experience (it is anticipated that approximately 40% of subjects will be VKA-naive);
- •4.A moderate to high risk of stroke, as defined by CHADS2 index score of at least 2, is required to be eligible for the study. The CHADS2 scoring is performed by assigning 1 point each for a history of congestive heart failure, hypertension, age = 75 years, or diabetes mellitus; and by assigning 2 points for history of stroke or TIA
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects who meet any of the criteria below will be disqualified from entering the study.
- •1.Transient AF secondary to other reversible disorders (e.g., thyrotoxicosis, cardiac or thoracic surgery, pneumonia, severe anemia);
- •2.Subjects with moderate or severe mitral stenosis, unresected atrial myxoma, or a mechanical heart valve (subjects with bioprosthetic heart valves and/or valve repair can be included);
- •3.Subjects for whom the AF management plan is rhythm control with subsequent discontinuation of oral anticoagulation if sinus rhythm is restored or maintained, including subjects in whom successful electrical or surgical ablation has been performed or is planned during the course of the study;
- •4.Subjects with any contraindication for anticoagulant agents;
- •5.Subjects with conditions associated with high risk of bleeding such as past history of spontaneous intracranial, intraocular, spinal, retroperitoneal, or intra-articular bleeding; overt gastrointestinal (GI) bleeding or active ulcer within the previous year; recent severe trauma, major surgery, or deep organ biopsy within the previous 10 days; active infective endocarditis; uncontrolled hypertension (blood pressure [BP] above 170/100 mmHg); or hemorrhagic disorder including known or suspected hereditary or acquired bleeding or coagulation disorder;
- •6.Subjects receiving thienopyridines (such as ticlopidine or clopidogrel) or other non-aspirin antiplatelet agents that cannot be stopped at randomization, or who are anticipated to receive non-aspirin antiplatelet agents as chronic therapy during the study;
- •7.Subjects receiving chronic cyclosporine for organ transplant, rheumatoid arthristis, or psoriasis;
- •8.Subjects receiving prohibited concomitant medications (fibrinolytics, non-study anticoagulants other than those used as a bridge to/from study drug, chronic non-aspirin NSAID use for > 4 days/week or for a chronic condition, potent P-gp inhibitors [ritonavir, cyclosporine, ketoconazole, itraconazole, erythromycin, clarithromycin];
- •9.Subjects with acute MI, stroke, acute coronary syndrome (ACS), or percutaneous coronary intervention (PCI) within the previous 30 days;
- •10.Subjects with active liver disease or persistent (confirmed by repeat assessment within a week) elevation of liver enzymes/bilirubin:
- •ALT or AST = 2 times the ULN,
- •TBL =1.5 times the ULN,
- •ALP =2 times the ULN;
- •11.Subjects with severe renal insufficiency (calculated CrCL <30 mL/min);
- •12.History of positive Hepatitis B antigen or Hepatitis C antibody;
- •13.Any other clinically relevant laboratory abnormality as judged by the Investigator;
- •14.Subjects receiving antiretroviral therapy for human immunodeficiency virus (HIV) infection or likely to receive such therapy during the study;
- •15.Subjects with hemoglobin < 10 g/dL or platelet count < 100,000 cells/µL or white blood cell count (WBC) < 3000 cells/µL;
- •16.Subjects with pre-planned invasive procedures (other than routine endoscopy) or surgeries in which bleeding is anticipated during the study period;
- •17.Subjects who received any investigational drug or device within 30 days prior to randomization, or plan to receive such investigational therapy during the study period;
- •18.Subjects previously randomized in a DU-176b study;
- •19.Females of childbearing potential including including the following:
- •Females with a history of tubal ligation;
- •Females less than 2 years postmenopausal;
- •20.Subjects with the following diagnoses or situations:
研究者
相似试验
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used and approved drug called warfarin in patients with an abnormal heart beat disease called atrial fibrillation. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-004522-16-DKDaiichi Sankyo Pharma Development20,500
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used and approved drug called warfarin in patients with an abnormal heart beat disease called atrial fibrillation. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 14.1Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-004522-16-DEDaiichi Sankyo Pharma Development20,500
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MULTI-CENTER, MULTI-NATIONAL STUDY FOR EVALUATION OF EFFICACY AND SAFETY OF DU-176B VERSUS WARFARIN IN SUBJECTS WITH ATRIAL FIBRILLATION – Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation (ENGAGE-AF) - ENGAGE AF TIMI-48Reduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 9.1Level: LLTClassification code 10003658Term: Atrial fibrillationEUCTR2008-004522-16-HUDaiichi Sankyo Pharma Development16,500
进行中（未招募）
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP,MULTI-CENTER, MULTI-NATIONAL STUDY FOR THE EVALUATION OF EFFICACY AND SAFETY OF (LMW) HEPARIN/EDOXABAN VERSUS (LMW) - Evaluation of edoxaban vs. warfarin in subjects with symptomatic venous thromboembolism (VTE)Patients with acute symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE)MedDRA version: 9.1Level: LLTClassification code 10051055MedDRA version: 9.1Level: LLTClassification code 10037377EUCTR2009-014290-40-ITDAIICHI SANKIO DEVELOPMENT LIMITED7,500
进行中（未招募）
不适用
ate development study which compares the effectiveness and safety of a not yet approved drug called edoxaban versus a widely-used and approved drug called warfarin in patients with an abnormal heart beat disease called atrial fibrillation. The study is double-blind (that is when neither the patient nor the investigator know which of the 2 drugs the patient is receiving) and is being conducted in many countries around the worldReduction of Stroke and/or systemic embolic event (SEE) in subjects with atrial fibrillation (AF).MedDRA version: 15.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2008-004522-16-CZDaiichi Sankyo Pharma Development20,500